Acurx Pharmaceuticals Stock Earnings Reports

Key points for investors:

- Clinical strategy: Acurx is initiating an open-label 20-patient pilot trial of ibezapolstat in multiply recurrent C. difficile infection (rCDI) to inform a planned active-controlled Phase III registration trial. The company is pursuing two parallel regulatory pathways: a Phase III program in acute CDI (potentially one pivotal trial if FDA guidance is applied) and an LPAD pathway for rCDI following the exploratory study and a pivotal trial. The company expects first patient in the rCDI pilot in roughly August 2026 (start-up currently underway).

- Strong Phase II signal: Acurx emphasizes Phase II ibezapolstat results showing a 96% cure rate and no recurrences in cured patients (25/25 at 1 month; 5/5 at 3 months for those observed), which the company believes supports potential to both treat acute CDI and prevent recurrence.

- Regulatory environment: FDA published C. difficile guidance that formalizes the potential to rely on a single adequate and well-controlled trial supported by "confirmatory evidence of substantial efficacy." Acurx has a meeting scheduled with FDA to discuss application of this guidance to their program.

- Differentiation / science: Ibezapolstat and related DNA Pol IIIC inhibitors show microbiome-sparing properties in preclinical and clinical assessments (important to reducing recurrence). Preclinical data also show systemic Pol IIIC compounds achieving therapeutic plasma levels and activity vs. MRSA while preserving microbiome diversity.

- Intellectual property: Recent patent grants (including Korea and U.S.) expand protection for DNA Pol IIIC inhibitors and ibezapolstat uses; Acurx reports 10 granted patents across major jurisdictions.

- Financials / runway: Cash of $9.3M as of March 31, 2026 (up from $7.6M at year-end) following ~$3.1M gross proceeds from equity line purchases and a registered direct offering/short-term warrants completed in April. R&D expense decreased to $0.3M (Q1 2026) vs $0.6M prior year; G&A $1.4M vs $1.6M prior year. Net loss $1.7M ($0.62 per diluted share) for Q1 2026. Management states funding plus remaining equity line availability supports the exploratory rCDI trial and they continue to pursue funding for Phase III.

- Timeline and trial design notes: Plan to follow patients for standard 1-month recurrence endpoint and additional follow-up (e.g., 8 weeks/2 months consistent with live-biologic comparators). The rCDI pilot will inform Phase III design; Phase III in acute CDI may be eligible for single-trial registration under the new FDA guidance, subject to FDA agreement.